Article
Dermatology
Matthias Augustin, Kristian Reich, Paul Yamauchi, Andreas Pinter, Jerry Bagel, Swapnil Dahale, Ruquan You, Gerard Bruin, Jimena Djimopoulos, Bertrand Paguet, Pascal Charef, Manmath Patekar, Deborah Keefe
Summary: Secukinumab 300 mg every 2 weeks demonstrated superior and sustained efficacy compared with every 4 weeks in patients with moderate-to-severe plaque psoriasis who had a higher bodyweight. Uptitration to the every 2 weeks regimen provided additional benefits for nonresponders.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Sonsoles Berenguer-Ruiz, Mario Aparicio-Dominguez, Perdo Herranz-Pinto, Ricardo Ruiz-Villaverde, Anna Lopez-Ferrer, Jorge Santos-Juanes, Lourdes Rodriguez Fernandez-Freire, Mercedes Hospital-Gil, Salvador Arias-Santiago, Gregorio Carretero-Hernandez, Almudena Mateu-Puchades, Marta Ferran, Elena del Alcazar, Sergio Santos-Alarcon, Francisco Javier Garcia-Latasa de Aranibar, Isabel Belinchon-Romero, Alvaro Gonzalez-Cantero, Diana Ruiz-Genao, Noemi Eiris-Salvado, Vicenc Rocamora-Duran, Raquel Rivera-Diaz, Pablo de la Cueva, Esteban Dauden, Laura Salgado-Boquete, Mar Llamas-Velasco
Summary: This study retrospectively evaluated the effectiveness and safety of tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis in routine clinical practice. The results showed that tildrakizumab had good efficacy in reducing disease severity and improving quality of life, and it was found to be safe in a routine clinical setting.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Medicine, General & Internal
Ran Pan, Xiaolun Wang, Min Shu, Jaydeep Das, Manik Kalra, Zhidong Wang
Summary: The efficacy of SEC in the treatment of patients with moderate-to-severe plaque psoriasis is well demonstrated through NMA.
CHINESE MEDICAL JOURNAL
(2022)
Editorial Material
Orthopedics
David Figueroa
Summary: Lower tourniquet inflation pressures in patients undergoing total knee arthroplasty were found to reduce postoperative pain at the tourniquet inflation site and surgical site for up to 2 weeks compared to higher pressures.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
(2021)
Article
Dermatology
Augusta Ortolan, Mariagrazia Lorenzin, Giovanni Leo, Francesca Pampaloni, Francesco Messina, Andrea Doria, Stefano Piaserico, Roberta Ramonda
Summary: This study confirmed the good efficacy of Secukinumab in both PsO and PsA patients, but the presence of arthritis may affect drug survival.
Article
Dermatology
Nina Magnolo, Kulli Kingo, Vivian Laquer, John Browning, Adam Reich, Jacek C. Szepietowski, Deborah Keefe, Rafal Mazur, Prayashi Ghelani, Pascal Forrer, LindaAnn Wraith, Manmath Patekar
Summary: The study evaluated the efficacy and safety of two secukinumab dosage regimens in pediatric patients with moderate to severe plaque psoriasis, showing both doses were superior to historical placebo and well tolerated by the patients.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Review
Obstetrics & Gynecology
Johan Agren, Jeffrey L. Segar, Fanny Soderstrom, Edward F. Bell
Summary: The encouraging outcomes of extremely preterm infants from centers taking active approaches to their care have prompted discussions on optimal medical management. However, there is limited data to guide evidenced-based approaches to fluid and electrolyte management in this population. This perspective paper highlights the developmental physiological properties of the kidney and skin and provides recommendations for initial fluid and electrolyte management based on novel data and published literature.
SEMINARS IN PERINATOLOGY
(2022)
Article
Dermatology
Alexander Egeberg, Lars Erik Kristensen, Luis Puig, Phoebe Rich, Saxon D. Smith, Alyssa Garrelts, Kyoungah See, Thorsten Holzkaemper, Konstantinos Fotiou, Christopher Schuster
Summary: Two network meta-analyses were conducted to compare the efficacy of biologics in treating nail psoriasis. The results showed that ixekizumab had the highest probability of achieving complete resolution of nail psoriasis.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2023)
Article
Dermatology
Elena del Alcazar, Anna Lopez-Ferrer, Alvaro Martinez-Domenech, Ricardo Ruiz-Villaverde, Ma. del Mar Llamas-Velasco, Vicenc Rocamora, Marc Julia, Jaime Notario, Lourdes Rodriguez Fernandez-Freire, Antonio Sahuquillo-Torralba, David Vidal, Raquel Rivera, Gregorio Carretero, Almudena Mateu, Pablo de la Cueva, Jose Manuel Carrascosa
Summary: This study aimed to assess the effectiveness and safety of guselkumab in the treatment of moderate to severe plaque psoriasis in routine clinical practice. The results showed that guselkumab had significant efficacy and good safety profile at 24 weeks.
DERMATOLOGIC THERAPY
(2022)
Article
Obstetrics & Gynecology
Ariel Sklar, Jeanelle Sheeder, Anne R. Davis, Carrie Wilson, Stephanie B. Teal
Summary: This study compared maternal morbidity in women with preterm premature rupture of membranes who chose either expectant management or termination of pregnancy. The results showed that women who chose expectant management had higher morbidity rates, with an increased risk of chorioamnionitis and postpartum hemorrhage compared to those who chose termination of pregnancy. Expectant management was also associated with a higher likelihood of admission to the maternal intensive care unit and unplanned hysterectomy. The study suggests that expectant management increases maternal morbidity compared to termination of pregnancy.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2022)
Article
Medicine, General & Internal
Yan Zhao, Lin Cai, Xiao-Yang Liu, Heng Zhang, Jian-Zhong Zhang
Summary: This real-life study in Chinese patients with moderate-to-severe plaque psoriasis demonstrated that both secukinumab 150 and 300 mg were effective and well tolerated, with better clinical efficacy observed in biologic-naive patients.
CHINESE MEDICAL JOURNAL
(2021)
Article
Dermatology
K. Reich, J. Sullivan, P. Arenberger, S. Jazayeri, U. Mrowietz, M. Augustin, B. Elewski, R. You, P. Regnault, J. A. Frueh
Summary: Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2 center dot 5 years in nail psoriasis, with significant sustained quality-of-life improvements and a favorable safety profile. No new safety findings were observed, indicating the long-term safety of Secukinumab in treating nail psoriasis.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Yunyang Zhao, Julie McCormack, Miriam Kimel, Joseph F. Merola
Summary: This study describes the patient-reported clinical and quality-of-life outcomes after initiating ixekizumab. The results show that improvements in patients' condition can be seen as early as 2 weeks after initiation. The improvements reported by patients continue throughout the 24-week treatment period.
DERMATOLOGY AND THERAPY
(2023)
Article
Dermatology
Luca Stingeni, Giovanna Malara, Andrea Conti, Luisa Di Costanzo, Carlo Giovanni Carrera, Martina Burlando, Piergiorgio Malagoli, Maria Letizia Musumeci, Federico Bardazzi, Valeria Brazzelli, Paolo Amerio, Clara De Simone, Sara Trevisini, Anna Balato, Matteo Megna, Francesco Loconsole, Catia De Felice, Marta Bartezaghi, Alice Rausa, Elisabetta Aloisi, Roberto Orsenigo, Antonio Costanzo
Summary: This study analyzed the gender-related differences in the efficacy of secukinumab 300 mg and its impact on quality of life in patients with moderate to severe psoriasis. The results showed that secukinumab was effective in treating psoriasis and improving quality of life, regardless of gender.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2023)
Article
Dermatology
Xi-Bei Chen, Yu-Xin Zheng, Li-Ran Ye, Xue-Yan Chen, Xiao-Yong Man
Summary: This study investigated the feasibility, efficacy, and safety of gradually increasing the secukinumab dosing interval in patients with moderate-to-severe psoriasis. The results showed that a majority of patients achieved PASI 75 improvement at week 36 after using the drug.
DERMATOLOGIC THERAPY
(2022)